Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Alumis Inc., a San Francisco-based biotech, completed its IPO in June last year, raising ~$250m, and focuses on developing TYK2 inhibitors ESK-001 and A-005. Alumis' ESK-001 is in Phase 3 trials for ...

Fidelity MSCI Health Care Index ETF offers long-term growth potential, leveraging demographic tailwinds and biotech innovation, but requires patience through cycles ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The MarketWatch News Department was not involved in the creation of this content. BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging artificial intelligence ...

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, ...

Earlier in February 2026, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep combined with bevacizumab and FOLFIRI for second-line treatment of KRAS-mutant, ...